In March 2024, physicians at Mass General Brigham attempted an ambitious variation of CAR-T therapy on three patients battling recurrent glioblastoma, among the most lethal brain cancers known to medicine.

Rather than following standard protocols, they enhanced an existing CAR-T approach with targeted antibodies. This combination effectively sharpened the immune system’s precision inside the brain, directing its focus toward malignant cells.

The treatment was administered directly into the cerebrospinal fluid surrounding the brain and spinal cord. This delivery method placed engineered immune cells in immediate proximity to the tumor, maximizing their potential impact.

The results astonished the medical team. One patient experienced tumor shrinkage of 18.5 percent within just two days, which expanded to over 60 percent within ten weeks.

Another patient demonstrated rapid regression of their cancer. The third showed visible changes on MRI scans within only five days of receiving the experimental therapy.

These outcomes represent early, fragile findings from merely three individuals—not a proven cure. Yet for a malignancy long defined by grim prognoses and limited options, this small trial offers something remarkable.

It provides a first, undeniable glimpse that even glioblastoma, a seemingly invincible foe, may finally have revealed a vulnerability. The path ahead remains long, but hope now has a foothold where none existed before.